Exhibit 9

State of California ex rel. Ven-A-Care of the Florida Keys, Inc. v. Abbott Labs, Inc. et al., Civil Action No. 03-11226-PBS

Exhibit to the November 25, 2009 Declaration of Philip D. Robben in Support of Defendants' Joint Motion for Partial Summary Judgment

December 11, 2008

	33
UNITED STATES	DISTRICT COURT
DISTRICT OF	MASSACHUSETTS
	-x
In re: PHARMACEUTICAL INDUSTRY)
AVERAGE WHOLESALE PRICE)
LITIGATION)
	~)
United States of America ex rel	.) MDL No. 1456
Ven-A-Care of the Florida Keys,)
Inc. v. Abbott Laboratories,) Civil Action
Inc., Civil Action No. 06-) No. 01-12257-PBS
11337-PBS; and United States of)
America ex rel. Ven-A-Care of) Honorable
the Florida Keys, Inc., v. Dey,) Patti B. Saris
Inc., et al., Civil Action No.)
05-11084-PBS; and United States)
of America ex rel. Ven-A-Care)
of the Florida Keys, Inc., v.)
Boehringer Ingelheim Corp., et)
al., Civil Action No. 07-10248-)
PBS)
	-x

December 11, 2008

464

- access would be an issue.
- O. (By Mr. Reale) So it's fair to say that
- 3 the State's determination of estimated
- 4 acquisition cost is a balance of all the factors
- 5 that we talked about today, not solely the cost
- of the drug to some pharmacies?
- 7 A. Well, again, and I know I've said this
- and repeated it a lot of times, but there is
- 9 always that variance off of the AWP. So we know
- that AWP is discounted. We don't want to -- so
- we're going to set something that's a balance
- that will allow access to be maintained by the
- 13 providers.
- Q. And it's a balance, on the one hand,
- between Arkansas' own budget pressures and the
- need to try to ensure the efficiency and economy
- in its Medicaid program, and on the other hand,
- we have pressures from providers who voluntarily
- participate in the program and the need to ensure
- that there's access for Medicaid patients. Would
- you say that's a fair representation?
- MS. MOSLEY-SIMS: Objection.

Henderson Legal Services, Inc.

202-220-4158 www.hendersonlegalservices.com

December 11, 2008

465

1 I would say it's a fair statement. Α. 2 don't know if it's complete, but it's fair. 3 (By Mr. Reale) And there may be other 4 factors that play in the cost, determination of 5 estimated acquisition cost. Yes? б Α. There could be. Right off the top of 7 my head, I don't have any answer for you. MR. REALE: Okay. I have no questions 9 further at this time. I don't know if Eric or 10 Anne want to go next, but I know you both have 11 documents, so give me a minute to pull those out 12 for you. 13 MR. BERLIN: We do, and actually, we 14 hadn't spoken as to which of us should go first. 15 Anne, do you have a preference? 16 I don't. Either way. MS. MANGIARDI: 17 (Whereupon an off-the-record was held.) 18 [Marked Exhibit Abbott-ARK 001] 19 20 EXAMINATION QUESTIONS BY MR. BERLIN: 21 First, actually, I've already forgot. Q. 22 You prefer Suzette, but if I have to call you by

Henderson Legal Services, Inc.

December 11, 2008

537

- represent any actual price which will or has been
- charged or paid for this product.
- Generally, it is Dey's practice to set
- an AWP before a product is first sold and not to
- 5 subsequently change that AWP. We understand that
- 6 this is consistent with industry practice. We
- believe this to be clearly understood by state
- 8 and federal Medicaid regulator. Dey has chosen
- 9 to change the AWP on these products at this time
- 10 principally due to current conditions in the
- 11 marketplace."
- Q. Thank you.
- A. You're welcome.
- Q. Are those statements about AWP and WAC
- consistent with your earlier testimony about what
- you understood those terms to mean?
- MS. OBEREMET: Objection.
- A. Again, all I stated earlier was that
- WAC, what I know to be is wholesale acquisition
- cost, and it's not available on every product,
- 21 and that we don't utilize WAC for our
- reimbursement. AWP is average wholesale price,

Henderson Legal Services, Inc.

202-220-4158

www.hendersonlegalservices.com

December 11, 2008

538

- that -- there are discounts off of AWP that have
- variables to them. And, as we just discussed,
- 3 that it was my understanding that AWP is what was
- 4 presented to First DataBank. I don't know that
- 5 that's exactly what this -- this -- the whole
- ⁶ paragraph states.
- Q. (By Ms. Mangiardi) Okay, Thank you.
- ⁸ And do you see the last sentence at the bottom,
- 9 which says that if you need additional
- information, please feel free to contact Virginia
- Farret. I believe you testified earlier that you
- 12 had never -- you had never contacted Dey about
- 13 anything?
- 14 A. Not -- no.
- Q. That is correct?
- A. I -- I haven't contacted them about a
- document such as this.
- Q. Do you know if anyone else at DHS has
- 19 ever done so?
- A. Not that I'm aware of.
- Q. Would you agree that Dey here is
- expressly informing you that AWP does not

Henderson Legal Services, Inc.

December 11, 2008

539

- represent the actual price charged or paid for
- 2 the product?
- MR. BERLIN: Objection.
- A. Based on the document that's -- it is
- 5 stating that it is not the actual price.
- MS. MANGIARDI: Now, John, could you
- 7 please hand the witness the document behind Tab
- 8 5?
- 9 MR. REALE: I've handed the witness a
- document which has been previously marked as Dey
- 11 Exhibit 226.
- Q. (By Ms. Mangiardi) Now, this document
- is a chart which represents the AWPs and WAC
- 14 reported by Dey to First DataBank for
- 15 Ipratropium, 25 milliliters, NDC No. 49502-68503.
- A. Okay. I'm sorry. I forgot to respond.
- 17 I'm just reading and think you're going to
- 18 continue.
- Q. It wasn't really a question. It was
- more for the record. Please take a second to
- look it over and tell me when you're ready for
- ²² questions.

Henderson Legal Services, Inc.

202-220-4158

www.hendersonlegalservices.com